Investor Presentation

1. **Financial Highlights**: For Q3 FY25, Akums Drugs and Pharmaceuticals reported a total income of ₹10,250 Cr, slightly down from ₹10,918 Cr in Q3 FY24. Adjusted EBITDA rose to ₹1,359 Cr with a margin of 13.3%, up from 11.1% a year earlier.

Adjusted PAT increased to ₹663 Cr, marking a 15% YoY growth.

For the nine months of FY25, total income reached ₹30,972 Cr, while adjusted PAT was ₹1,903 Cr, reflecting an overall positive performance.

2. **Strategic Initiatives and Growth Drivers**: The company secured a €200 million contract to manufacture and supply products for European markets, which will significantly enhance its global footprint.

Domestic operations saw a strong growth trajectory with new facilities contributing positively.

Seven DGCI approvals were received in Q3, indicating progress in innovation and product development.

3. **Business Developments**: Akums has formed a partnership with Jagdale to expand its Ready-to-Drink product offerings and acquired exclusive rights to develop and market innovative products from Triple Hair and Caregen for the Indian market.

4. **Market Position and Competitive Advantage**: Akums holds a leading position in the Indian CDMO space, serving major players in various pharmaceutical segments.

The company's robust infrastructure and diverse product offerings provide a competitive advantage in both domestic and international markets.

5. **Investor Implications**: The secured contracts and strong growth indicators coupled with strategic expansions present a positive outlook for investors.

Watch closely as Akums aims to leverage its innovations and partnerships to sustain growth momentum in the upcoming fiscal periods.